Emerging role of human microbiome in cancer development and response to therapy: special focus on intestinal microflora

Table 4 Association between commensal microbiome composition and clinical outcomes of immunotherapy

Therapy	Types of malignancy	Responder	Non-responder	References
Anti-PD1	NSCLC	Akkermansia muciniphila, Enterococcus hirae		Routy et al. [163]
Anti-PD1	Melanoma	Faecalibacterium	Bacteroidales	Gopalakrishnan et al. [166]
Anti-PD1	Metastatic melanoma	Bifidobacterium longum, Collinsella aerofaciens, and Enterococcus faecium	Ruminococcus obeum, Roseburia intestinalis	Matson et al. [167]
Anti-CTLA4	Metastatic melanoma	Firmicutes phylum, e.g. Faecalibacterium	–	Chaput et al. [201]
Anti-CTLA4 Anti-PD1	Metastatic melanoma	Bacteroides caccae, Streptococcus parasanguinis	–	Frankel et al. [265]
Anti-CTLA4 Anti-PD1	Metastatic melanoma	Faecalibacterium prausnitzii, Holdemania filiformis, Bacteroides thetaiotamicron	–	Frankel et al. [265]
Pembrolizumab	Metastatic melanoma	Dorea formicigenerans	–	Frankel et al. [265]

Anti-PD1 anti-programmed cell death 1 protein, Anti-CTLA-4 anti- cytotoxic T-lymphocyte-associated protein 4

ISSN: 1479-5876